PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas
Soft-tissue sarcomas (STS) are a group of rare, Napkin Set heterogeneous, and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies.In the quest for new treatments, the immune system represents an attractive therapeutic target.Recently, PD1/PDL1 inhibitors showed very promising results in patients with solid t